Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
42%
Ph early_phase_1
3
25%
Ph not_applicable
4
33%

Phase Distribution

8

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
3(25.0%)
Phase 1Safety & dosage
5(41.7%)
N/ANon-phased studies
4(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(1)
Other(9)

Detailed Status

unknown9
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 13 (25.0%)
Phase 15 (41.7%)
N/A4 (33.3%)

Trials by Status

completed18%
recruiting217%
unknown975%

Recent Activity

2 active trials
Showing 5 of 12
recruitingnot_applicable

Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

NCT06993493
recruitingnot_applicable

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

NCT06983964
unknownearly_phase_1

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

NCT04626765
unknownearly_phase_1

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

NCT04626726
unknownearly_phase_1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

NCT04626739
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06993493Not Applicable

Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

Recruiting
NCT06983964Not Applicable

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

Recruiting
NCT04626765Early Phase 1

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Unknown
NCT04626726Early Phase 1

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Unknown
NCT04626739Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Unknown
NCT04447547Not Applicable

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Unknown
NCT03232619Phase 1

CD19-CART Treatment for ALL

Completed
NCT04546893Not Applicable

Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Unknown
NCT04012879Phase 1

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

Unknown
NCT04012892Phase 1

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Unknown
NCT03263208Phase 1

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Unknown
NCT03146533Phase 1

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Unknown

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12